Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (101-110 of 336) with videos related to

Pageof 34
Sort By:
Journal of Oncology Practice|November 2, 2010
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond, Daniel F Hayes, Antonio C Wolff, et al.
Annals of Surgical Oncology|March 30, 2002
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancerVered Stearns, C Alexander Ewing, Rebecca Slack, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2021
Improving Oncology-Pathology Collaboration in Resource-Limited Settings: An American Society of Clinical Oncology/College of American Pathologists InitiativeJose Angel Sanchez, Silvia Portillo, Matthew A Zarka, et al.
Clinical Breast Cancer|April 3, 2017
Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor DiscontinuationN Lynn Henry, Kelly Speth, Anneleen Lintermans, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2005
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing schemeAnne F Schott, James M Rae, Kent A Griffith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2014
Reply to R. Bhargava et al and K. Lambein et alAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Journal of Oncology Practice|September 4, 2012
Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulatorShannon Wills, Anita Ravipati, Padmaja Venuturumilli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2017
Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research StatementLaura A Levit, Raymond P Perez, David C Smith, et al.
Breast Cancer Research and Treatment|January 10, 2024
Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancerElizabeth Joyce, Xueting Tao, Vered Stearns, et al.
Breast Cancer Research and Treatment|February 2, 2019
Factors influencing the use of extended adjuvant endocrine therapyKunal C Kadakia, Kelley M Kidwell, Debra L Barton, et al.
Pageof 34

Showing results (101-110 of 336) with videos related to

Sort By:
Pageof 34
Journal of Oncology Practice|November 2, 2010
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerM Elizabeth H Hammond, Daniel F Hayes, Antonio C Wolff, et al.
Annals of Surgical Oncology|March 30, 2002
Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancerVered Stearns, C Alexander Ewing, Rebecca Slack, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 19, 2021
Improving Oncology-Pathology Collaboration in Resource-Limited Settings: An American Society of Clinical Oncology/College of American Pathologists InitiativeJose Angel Sanchez, Silvia Portillo, Matthew A Zarka, et al.
Clinical Breast Cancer|April 3, 2017
Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor DiscontinuationN Lynn Henry, Kelly Speth, Anneleen Lintermans, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2005
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing schemeAnne F Schott, James M Rae, Kent A Griffith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2014
Reply to R. Bhargava et al and K. Lambein et alAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Journal of Oncology Practice|September 4, 2012
Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulatorShannon Wills, Anita Ravipati, Padmaja Venuturumilli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2017
Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research StatementLaura A Levit, Raymond P Perez, David C Smith, et al.
Breast Cancer Research and Treatment|January 10, 2024
Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancerElizabeth Joyce, Xueting Tao, Vered Stearns, et al.
Breast Cancer Research and Treatment|February 2, 2019
Factors influencing the use of extended adjuvant endocrine therapyKunal C Kadakia, Kelley M Kidwell, Debra L Barton, et al.
Pageof 34